Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'
Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
